Korro Bio has received approvals in Australia to start the Phase I/IIa REWRITE trial for KRRO-110, targeting alpha-1 antitrypsin deficiency.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Korro Bio has received approvals in Australia to start the Phase I/IIa REWRITE trial for KRRO-110, targeting alpha-1 antitrypsin deficiency.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.